We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$272M
AUM Growth
-$70.2M
Cap. Flow
-$30.4M
Cap. Flow %
-11.2%
Top 10 Hldgs %
40.84%
Holding
92
New
12
Increased
37
Reduced
27
Closed
16

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$8.78M
2
WAT icon
Waters Corp
WAT
+$8.33M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$6.57M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.23M
5
UTHR icon
United Therapeutics
UTHR
+$3.6M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
2
ABBV icon
AbbVie
ABBV
+$7.41M
3
IDXX icon
Idexx Laboratories
IDXX
+$5.14M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.09M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.48%
2 Industrials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
76
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$190K 0.07%
115,577
-93,571
-45% -$194K
ABBV icon
77
AbbVie
ABBV
$440B
– –
-45,731
Closed -$7.41M
ANAB icon
78
AnaptysBio
ANAB
$1.69B
– –
-37,285
Closed -$922K
ATRC icon
79
AtriCure
ATRC
$2.22B
– –
-25,236
Closed -$1.66M
BCRX icon
80
BioCryst Pharmaceuticals
BCRX
$2.71B
– –
-476,978
Closed -$7.76M
CRL icon
81
Charles River Laboratories
CRL
$13.6B
– –
-10,000
Closed -$2.84M
GOSS icon
82
Gossamer Bio
GOSS
$86.8M
– –
-200,185
Closed -$1.74M
IDXX icon
83
Idexx Laboratories
IDXX
$45B
– –
-9,388
Closed -$5.14M
MRVI icon
84
Maravai LifeSciences
MRVI
$861M
– –
-77,389
Closed -$2.73M
NRIX icon
85
Nurix Therapeutics
NRIX
$2.76B
– –
-20,663
Closed -$289K
OM icon
86
Outset Medical
OM
$84.6M
– –
-5,440
Closed -$3.71M
TFX icon
87
Teleflex
TFX
$6.03B
– –
-12,500
Closed -$4.43M
VSTM icon
88
Verastem
VSTM
$629M
– –
-15,896
Closed -$269K
SCTL
89
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-671,817
Closed -$1.21M
MRTX
90
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-15,236
Closed -$1.25M
MTEM
91
DELISTED
Molecular Templates, Inc.
MTEM
– –
-6,914
Closed -$358K
SRRA
92
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-151,915
Closed -$4.87M
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Parkman Healthcare Partners held 92 positions worth $272M, down 21% from $342M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $30.4M in Q2 2022, closing 16 positions and reducing 27 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $7.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Elevance Health worth $8.57M.

  • Parkman Healthcare Partners's largest Q2 2022 buy was Elevance Health: 17,750 shares worth $8.57M.
  • Parkman Healthcare Partners added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2022, an estimated $4.23M increase.
  • Parkman Healthcare Partners's biggest Q2 2022 reduction was Aclaris Therapeutics, cutting an estimated $5.09M.
  • Parkman Healthcare Partners fully exited BioCryst Pharmaceuticals in Q2 2022, selling an estimated $7.76M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $272M portfolio in Q2 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 16 in Q2 2022.
  • Parkman Healthcare Partners's portfolio value fell 21% quarter-over-quarter to $272M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.